We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+57.31%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$253M
AUM Growth
+$105M
Cap. Flow
+$69.1M
Cap. Flow %
27.37%
Top 10 Hldgs %
50.9%
Holding
95
New
29
Increased
11
Reduced
6
Closed
23

Top Buys

Rank Stock Value
1
AVDL
Avadel Pharmaceuticals
AVDL
+$8.24M
2
BHVN icon
Biohaven
BHVN
+$6.93M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$5.72M
4
LRMR icon
Larimar Therapeutics
LRMR
+$5.42M
5
HELP
Cybin Inc
HELP
+$5.3M

Top Sells

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$9.75M
2
ATXS
Astria Therapeutics
ATXS
+$7.32M
3
IMVT icon
Immunovant
IMVT
+$3.37M
4
ORIC icon
Oric Pharmaceuticals
ORIC
+$3.22M
5
CBAY
Cymabay Therapeutics
CBAY
+$2.62M

Sector Composition

Rank Sector Weight
1 Healthcare 85.9%
2 Consumer Discretionary 1.37%
3 Industrials 0.06%
4 Communication Services 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BTAI icon
76
PUT
BioXcel Therapeutics
BTAI
$27.8M
– –
-10,575
Closed -$499K
CRNX icon
77
Crinetics Pharmaceuticals
CRNX
$8.92B
– –
-65,000
Closed -$2.31M
BGMS
78
Bio Green Med Solution Inc
BGMS
$5.24M
– –
-158
Closed -$101K
CYTK icon
79
Cytokinetics
CYTK
$10.4B
– –
-20,000
Closed -$1.67M
DDI
80
DoubleDown Interactive
DDI
$588M
– –
-60,876
Closed -$447K
DMAC icon
81
DiaMedica Therapeutics
DMAC
$364M
– –
-287,698
Closed -$817K
FBIO icon
82
Fortress Biotech
FBIO
$88.7M
– –
-405,122
Closed -$1.22M
IMVT icon
83
Immunovant
IMVT
$8.25B
– –
-80,000
Closed -$3.37M
MSOS icon
84
AdvisorShares Pure US Cannabis ETF
MSOS
$880M
– –
-80,000
Closed -$561K
SDEV
85
Stablecoin Development Corp
SDEV
$52M
– –
-385
Closed -$13.8K
NVNO
86
enVVeno Medical
NVNO
$7.08M
– –
-9,842
Closed -$1.77M
FLNA
87
Filana Therapeutics
FLNA
$48.1M
– –
-13,000
Closed -$293K
FLNA
88
PUT
Filana Therapeutics
FLNA
$48.1M
– –
-47,000
Closed -$1.06M
SDOT icon
89
Sadot Group
SDOT
$12.7M
– –
-84
Closed -$67.4K
SGMT icon
90
Sagimet Biosciences
SGMT
$559M
– –
-483,181
Closed -$2.53M
TNXP icon
91
Tonix Pharmaceuticals
TNXP
$192M
– –
-169
Closed -$218K
CBAY
92
DELISTED
Cymabay Therapeutics
CBAY
– –
-111,000
Closed -$2.62M
PEPLW
93
DELISTED
PepperLime Health Acquisition Corporation Warrrant
PEPLW
– –
-367,500
Closed -$11.1K
TGVCW
94
DELISTED
TG Venture Acquisition Corp. Warrants
TGVCW
– –
-200,000
Closed -$2.96K
RACYW
95
DELISTED
Relativity Acquisition Corp. Warrant
RACYW
$0 ﹤0.01%
100,000
– –
1 2 3
4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Altium Capital Management held 95 positions worth $253M, up 72% from $147M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Altium Capital Management deployed $69.1M of net new capital in Q1 2024, opening 29 new positions and adding to 11 existing holdings. Its largest new stake was Avadel Pharmaceuticals: 553,057 shares worth $9.34M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was Astria Therapeutics, an estimated $7.32M trimmed.

  • Altium Capital Management's largest Q1 2024 buy was Avadel Pharmaceuticals: 553,057 shares worth $9.34M.
  • Altium Capital Management added most to Vera Therapeutics in Q1 2024, an estimated $3.39M increase.
  • Altium Capital Management's biggest Q1 2024 reduction was Astria Therapeutics, cutting an estimated $7.32M.
  • Altium Capital Management fully exited Alpha Architect 1-3 Month Box ETF in Q1 2024, selling an estimated $9.75M.
  • Altium Capital Management's ten largest holdings make up 51% of its $253M portfolio in Q1 2024.
  • Altium Capital Management opened 29 new positions and closed 23 in Q1 2024.
  • Altium Capital Management's portfolio value rose 72% quarter-over-quarter to $253M.

Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.